Venus Remedies Limited has informed the Exchange about Copy of Newspaper Publication

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+10.3%1-day move

₹1219.10

prior close

₹1280.05

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.0+0.0+0.0+10.3+15.8+21.5+27.6+34.0+32.1+43.0+58.2——

Up moveDown movePending

AI summary

Venus Remedies Limited has published its audited financial results for FY 2025-26 ended March 31, 2026. On a consolidated basis, total income grew to Rs. 65,289 from Rs. 52,652 in the previous year, representing approximately 24% growth. Profit after tax stood at Rs. 2,546 compared to Rs. 1,571 in the prior year, showing strong profitability improvement. EPS on consolidated basis is Rs. 76.89. On a standalone basis, revenue from operations was Rs. 8,734 and profit after tax was Rs. 1,121.51 with EPS of Rs. 33.89. The board has recommended a dividend of Rs. 10 per equity share (100%). The results were published on May 26, 2026.

Likely market impact

The results indicate healthy growth in both revenue and profitability for Venus Remedies. The strong PAT growth and dividend declaration are positive signals for shareholders. The stock trades on NSE (VENUSREM) and BSE (526953).